These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 8677581

  • 1. Low-dose cyproterone acetate plus mini-dose diethylstilbestrol--a protocol for reversible medical castration.
    Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD.
    Urology; 1996 Jun; 47(6):882-4. PubMed ID: 8677581
    [Abstract] [Full Text] [Related]

  • 2. Effectiveness of cyproterone acetate in achieving castration and preventing luteinizing hormone releasing hormone analogue induced testosterone surge in patients with prostate cancer.
    Appu S, Lawrentschuk N, Grills RJ, Neerhut G.
    J Urol; 2005 Jul; 174(1):140-2. PubMed ID: 15947599
    [Abstract] [Full Text] [Related]

  • 3. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
    Pathak AS, Pacificar JS, Shapiro CE, Williams SG.
    J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
    [Abstract] [Full Text] [Related]

  • 4. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
    Calais da Silva FE, Bono AV, Whelan P, Brausi M, Marques Queimadelos A, Martin JA, Kirkali Z, Calais da Silva FM, Robertson C.
    Eur Urol; 2009 Jun; 55(6):1269-77. PubMed ID: 19249153
    [Abstract] [Full Text] [Related]

  • 5. Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma.
    Pickles T, Agranovich A, Berthelet E, Duncan GG, Keyes M, Kwan W, McKenzie MR, Morris WJ, British Columbia Cancer Agency, Prostate Cohort Outcomes Initiative.
    Cancer; 2002 Jan 15; 94(2):362-7. PubMed ID: 11900222
    [Abstract] [Full Text] [Related]

  • 6. Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer.
    Fujii Y, Yonese J, Kawakami S, Yamamoto S, Okubo Y, Fukui I.
    BJU Int; 2008 May 15; 101(9):1096-100. PubMed ID: 18190637
    [Abstract] [Full Text] [Related]

  • 7. A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy.
    Nejat RJ, Rashid HH, Bagiella E, Katz AE, Benson MC.
    J Urol; 2000 Dec 15; 164(6):1891-4. PubMed ID: 11061874
    [Abstract] [Full Text] [Related]

  • 8. Results of a Dutch trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer and results of EORTC studies in prostatic cancer.
    Debruyne FM.
    Am J Clin Oncol; 1988 Dec 15; 11 Suppl 1():S33-5. PubMed ID: 2968760
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of disease flare with diethylstilbestrol diphosphate and chlormadinone acetate administration for two weeks prior to slow-releasing leuprolide acetate in prostatic cancer patients.
    Ohuchi H, Noguchi K, Kinoshita Y, Hosaka M, Kawasaki C, Miura T, Kondo I, Harada M.
    Hinyokika Kiyo; 2000 Aug 15; 46(8):531-6. PubMed ID: 11019371
    [Abstract] [Full Text] [Related]

  • 10. Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy.
    Bruchovsky N, Klotz L, Crook J, Goldenberg SL.
    Cancer; 2007 Mar 01; 109(5):858-67. PubMed ID: 17265527
    [Abstract] [Full Text] [Related]

  • 11. Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer.
    Bong GW, Clarke HS, Hancock WC, Keane TE.
    Urology; 2008 Jun 01; 71(6):1177-80. PubMed ID: 18279929
    [Abstract] [Full Text] [Related]

  • 12. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
    Miller N, Smolkin ME, Bissonette E, Theodorescu D.
    Cancer; 2005 Jun 15; 103(12):2499-506. PubMed ID: 15852361
    [Abstract] [Full Text] [Related]

  • 13. Testosterone recovery after prolonged androgen suppression in patients with prostate cancer.
    Yoon FH, Gardner SL, Danjoux C, Morton G, Cheung P, Choo R.
    J Urol; 2008 Oct 15; 180(4):1438-43; discussion 1443-4. PubMed ID: 18710743
    [Abstract] [Full Text] [Related]

  • 14. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
    Kobayashi T, Nishizawa K, Mitsumori K.
    Scand J Urol Nephrol; 2006 Oct 15; 40(3):198-203. PubMed ID: 16809259
    [Abstract] [Full Text] [Related]

  • 15. One year follow-up study of the association between chemical castration, sex hormones, beta-amyloid, memory and depression in men.
    Almeida OP, Waterreus A, Spry N, Flicker L, Martins RN.
    Psychoneuroendocrinology; 2004 Sep 15; 29(8):1071-81. PubMed ID: 15219659
    [Abstract] [Full Text] [Related]

  • 16. Effects of intermittent diethylstilbestrol diphosphate administration on the R3327 rat prostatic carcinoma.
    Russo P, Liguori G, Heston WD, Huryk R, Yang CR, Fair WR, Whitmore WF, Herr HW.
    Cancer Res; 1987 Nov 15; 47(22):5967-70. PubMed ID: 3664500
    [Abstract] [Full Text] [Related]

  • 17. [Intermittent androgen deprivation treatment of prostate cancer restarted at low level of serum prostate specific antigen: a pilot study].
    Maekawa S, Maegawa M, Ushida H, Inoue K, Kaneko Y, Ohmori K, Nishimura K.
    Hinyokika Kiyo; 2001 Aug 15; 47(8):553-5. PubMed ID: 11579594
    [Abstract] [Full Text] [Related]

  • 18. A phase 1-2 trial of diethylstilbestrol plus low dose warfarin in advanced prostate carcinoma.
    Klotz L, McNeill I, Fleshner N.
    J Urol; 1999 Jan 15; 161(1):169-72. PubMed ID: 10037391
    [Abstract] [Full Text] [Related]

  • 19. Duration of testosterone suppression after a 9.45 mg implant of the GnRH-analogue buserelin in patients with localised carcinoma of the prostate a 12-month follow-up study.
    Pettersson B, Varenhorst E, Petas A, Sandow J.
    Eur Urol; 2006 Sep 15; 50(3):483-9. PubMed ID: 16626856
    [Abstract] [Full Text] [Related]

  • 20. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
    Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, Jensen JK, Olesen TK, Schröder FH.
    BJU Int; 2008 Dec 15; 102(11):1531-8. PubMed ID: 19035858
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.